Abstract:Shaan Lalvani, Rebecca M Brown Department of Neurology, The Mount Sinai Hospital, New York, NY, USA Correspondence: Rebecca M Brown, MD, PhD, The Mount Sinai Hospital, Department of Neurology, 1216 5th Avenue, New York, NY, 10029, USA, Tel +1 2128248579, Email Neurofibromatosis Type I (NF1) is a complex genetic condition that affects multiple organ systems and presents a unique set of challenges for clinicians in its management. NF1 is a tumor predisposition syndrome that primarily affect the peripheral and central nervous systems via the impact of haploinsufficiency upon neural crest lineage cells including Schwann cells, melanocytes, fibroblasts, etc. NF1 can further lead to pathology of the skin, bones, visual system, and cardiovascular system, all of which can drastically reduce a patient's quality of life (QOL). This review provides a comprehensive examination of the many specialties required for the care of patients with Neurofibromatosis Type 1 (NF1). We delve into the pathogenesis and clinical presentation of NF1, highlighting its diverse manifestations and the challenges they pose in management. The review underscores the importance of a multidisciplinary approach to NF1, emphasizing how such an approach can significantly improve patient outcomes and overall QOL. Central to this approach is the role of the NF expert, who guides a multidisciplinary team (MDT) comprising healthcare professionals from many areas of expertise. The MDT collaboratively addresses the multifaceted needs of NF1 patients, ensuring comprehensive and personalized care. This review highlights the need for further investigation to optimize the workflow for NF1 patients in an MDT setting, and to improve implementation and efficacy. Keywords: multisystemic, multidisciplinary team, quality of life, neurofibromatosis, NF expert, NF1, tumor predisposition syndrome Neurofibromatosis Type I (NF1) is a tumor predisposition syndrome characterized by a genetic mutation in the NF1 gene that affects the growth and regulation of the nervous system. Haploinsufficiency (50% decrease of functional protein) of the NF1 gene product neurofibromin is due to loss of function of one allele. The result is an increase in the proliferation rate, autocrine and paracrine signaling, and inflammatory cell signaling of Schwann cell precursors in the neural crest population. 1 NF1 has the propensity to manifest in multiple organ systems, providing a just rationale for multidisciplinary management. The loss of one NF1 allele in all tissues of the body results in multi-system abnormalities that can immensely complicate a patient's treatment plan and greatly impact outcome measures. 2 This review will delve into the pathogenesis and clinical presentation of NF1, in addition to closely examining how a multidisciplinary approach can benefit outcomes and quality of life (QOL). Figure 1 Venn diagram that illustrates the NF expert's role in a Multidisciplinary NF1 Care Team. Figure 2 Schematic outlining the necessary specialties to be included when dealing with specific clinical manifestations of NF1. *For optimal management, it is advisable to consult with a NF expert for all these conditions, prior to referral to specialties included above. **Neurosurgery should be considered imperative when addressing skeletal malformations involving the spine. NF1 is the most common of the peripheral nerve tumor genetic syndromes, which also includes schwannomatosis and NF2-related schwannomatosis. Its incidence is approximately 1 in 3000 live births. The condition stems from a heterozygous mutation in the NF1 gene on Chromosome 17q11.2 that occurs during gametogenesis. The NF1 gene encodes the protein known as neurofibromin, a known tumor suppressor which inhibits the GDPase-activating domain (GAP) of the intracellular signaling protein Ras (rat sarcoma). Ras resides within a family of GTPases that is involved in promoting cellular proliferation. Loss of the wild type NF1 allele during propagation of cells in the Schwann lineage directly causes the growth of peripheral nerve sheath tumors and is the only mutation typically identified. 3 With regard to clinical presentation, the most apparent features of NF1 include cutaneous neurofibromas (CN) purportedly arising from small nerves of the skin, and plexiform neurofibromas (PN) that derive from Schwann cells supporting large peripheral nerves and can invest in multiple bundles of nerves (nerve plexi). The diagnostic criteria of NF1 (Table 1), were updated in 2021. NF1 patients are susceptible to both benign and malignant nerve sheath tumors, 4 as well as neurocognitive and developmental deficits, mood disorder, osseous lesions including dystrophic scoliosis and pseudoarthrosis, neuroendocrine tumors, breast cancer, and others. 2 T -Abstract Truncated-

Qol-30. Dietary Considerations For People With Nf1: A Systematic Review Of The Literature

Bone mineral density, vitamin D and osseous metabolism indices in neurofibromatosis type 1: A systematic review and meta-analysis

Evaluation and Factors of Quality of Life Among Patients With Neurofibromatosis Type 1-Associated Craniofacial Plexiform Neurofibromas.

Cutaneous Neurofibromas and Quality of Life in Adults With Neurofibromatosis Type 1

Quality of Life in Children with Neurofibromatosis Type 1: Agreement between Parents and Patients, and the Role of Disease Severity and Visibility

Evaluation of quality of life in adults with neurofibromatosis 1 (NF1) using the Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire

QOLP-02. HEALTH-RELATED QUALITY OF LIFE (HRQOL) AMONG PEDIATRIC PATIENTS WITH NEUROFIBROMATOSIS TYPE 1 (NF1) AND PLEXIFORM NEUROFIBROMA (PN) IN THE UNITED STATES: PERSPECTIVES OF THE PATIENTS AND CAREGIVERS

Age-dependent oral manifestations of neurofibromatosis type 1: a case-control study

Bone densitometry measurements in children with neurofibromatosis Type 1 using quantitative computed tomography

The Lack of Ad Hoc Neuropsychological Assessment in Adults with Neurofibromatosis: A Systematic Review

Quality of life in patients with neurofibromatosis type 1 and 2 in Canada

Neurofibromatosis Type 1: Optimizing Management with a Multidisciplinary Approach

Bone metabolism in patients with type 1 neurofibromatosis: key role of sun exposure and physical activity

Health Supervision for Children With Neurofibromatosis Type 1

A Systematic Review of Diagnostic Modalities and Strategies for the Assessment of Complications in Adult Patients with Neurofibromatosis Type 1

L-carnitine supplementation for muscle weakness and fatigue in children with neurofibromatosis type 1: A Phase 2a clinical trial

Cognition and behavior in adults with neurofibromatosis type 1

Perspective of Adults With Neurofibromatosis 1 and Cutaneous Neurofibromas

Epidemiology and Outcomes of Neurofibromatosis Type 1 (NF-1): Multicenter Tertiary Experience

Impact of neurofibromatosis type 1 on quality of life using the Skindex-29 questionnaire quality of life in NF1

The efficacy of statins for improving cognitive impairments in pediatric patients with neurofibromatosis type 1 (NF-1): a meta-analysis